AACR Virtual Meeting II Poster Session
EMD Serono’s Dr. O’Rourke, et. al. presents comparison of
HTG EdgeSeq technology
- Category:
- Past Events
EMD Serono’s Dr. O’Rourke, et. al. presents comparison of
HTG EdgeSeq technology
Platform comparison of HTG EdgeSeq and RNA-Seq for gene expression profiling of tumor tissue specimens.
Listen to HTG’s presentation on New End-User Bioinformatics Pipeline for Patient Stratification in Precision Medicine.
Call scheduled for today, May 13, at 4:30pm ET TUCSON, Ariz. , May 13, 2020 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today reported its financial results for the first quarter ended March 31,…
TUCSON, Ariz. , May 11, 2020 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM), a diagnostic company whose mission is to advance precision medicine, today announced that it will report its financial results for the first quarter ended March 31, 2020 after the market close on…
Virtual Podium presentation by Dr. James Cooley. Register now!
Increased product and product-related services revenue over prior year, benefitting from expanded menu of profiling assays and increased number of customers adopting technology Released new HTG EdgeSeq Reveal data analysis software (version 2.0.0) Call scheduled for today, March 25 , at 4:30pm ET…
TUCSON, Ariz. , March 17, 2020 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM), a diagnostic company whose mission is to advance precision medicine, today announced that it will report its financial results for the year ended December 31, 2019 after the market close on Wednesday…
Presentation Background: Diffuse large B-cell lymphoma (DLBCL) is the most common NHL in adults. Gene expression profiling (GEP) divides DLBCL according to the cell of origin (COO) into three subgroups: GCB, ABC and unclassifiable (UNC), exhibiting different mutational profiles.
Sarcomatoid Renal Cell Carcinoma Demonstrates an Immunosuppressive Tumor Microenvironment – Implication for Therapeutic Benefit in the Immunotherapy Era
Renal cell carcinoma (RCC) with sarcomatoid features (sRCC) is an aggressive form of RCC with poor response to conventional therapies. Immune checkpoint inhibitors have shown promising therapeutic effect for sRCC in recent small series and sRCC has demonstrated higher PD-L1 expression and PD-1 positive tumor-infiltrating lymphocytes compared to high-grade clear cell RCC (ccRCC). Our aim was to use multiplexed gene expression assays to gain a broader view of the underlying tumor microenvironment in sRCC.
TUCSON, Ariz. , Feb. 19, 2020 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today announced that John Lubniewski , President and CEO, will present a corporate overview at the SVB Leerink 9 th Annual…
Page last updated March 20, 2023